Randomized Evaluation of Two Drug-Eluting Stents With Identical Metallic Platform and Biodegradable Polymer But Different Agents (Paclitaxel or Sirolimus) Compared Against Bare Stents: 1-Year Results of the PAINT Trial


Autoria(s): LEMOS, Pedro A.; MOULIN, Bruno; PERIN, Marco A.; OLIVEIRA, Ludmilla A. R. R.; ARRUDA, J. Airton; LIMA, Valter C.; LIMA, Antonio A. G.; CARAMORI, Paulo R. A.; MEDEIROS, Cesar R.; BARBOSA, Mauricio R.; BRITO JR., Fabio S.; RIBEIRO, Expedito E.; MARTINEZ, Eulogio E.; PAINT Trial Investigators
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

19/10/2012

19/10/2012

2009

Resumo

Objectives: We tested two novel drug-eluting stents (DES), covered with a biodegradable-polymer carrier and releasing paclitaxel or sirolimus, which were compared against a bare metal stent (primary objective). The DES differed by the drug, but were identical otherwise, allowing to compare the anti-restenosis effects of sirolimus versus paclitaxel (secondary objective). Background: The efficacy of novel DES with biodegradable polymers should be tested in the context of randomized trials, even when using drugs known to be effective, such as sirolimus and paclitaxel. Methods: Overall, 274 patients with de novo coronary lesions in native vessels scheduled for stent implantation were randomly assigned (2:21 ratio) for the paclitaxel (n = 111), sirolimus (n = 106), or bare metal stent (n = 57) groups. Angiographic follow-up was obtained at 9 months and major cardiac adverse events up to 12 months. Results: Both paclitaxel and sirolimus stents reduced the 9-month in-stent late loss (0.54-0.44 mm, 0.32-0.43 mm, vs. 0.90-0.45 mm respectively), and 1-year risk of target vessel revascularization and combined major adverse cardiac events (P < 0.05 for both, in all comparisons), compared with controls. Sirolimus stents had lower late loss than paclitaxel stents (P < 0.01), but similar 1-year clinical outcomes. There were no differences in the risk of death, infarction, or stent thrombosis among the study groups. Conclusion: Both novel DES were effective in reducing neointimal hyperplasia and 1-year re-intervention, compared to bare metal stents. Our findings also suggest that sirolimus is more effective than paclitaxel in reducing angiographic neointima, although this effect was not associated with better clinical outcomes. (C) 2009 Wiley-Liss, Inc.

Sahajanand Medical Technologies Pvt. (India)

CMS Medical (Brazil)

Identificador

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, v.74, n.5, p.665-673, 2009

1522-1946

http://producao.usp.br/handle/BDPI/21211

10.1002/ccd.22166

http://dx.doi.org/10.1002/ccd.22166

Idioma(s)

eng

Publicador

WILEY-LISS

Relação

Catheterization and Cardiovascular Interventions

Direitos

restrictedAccess

Copyright WILEY-LISS

Palavras-Chave #restenosis #randomized clinical trial #drug-eluting stents #coronary #angioplasty #atherosclerosis #CORONARY-ARTERY-DISEASE #REAL-WORLD #INTRAVASCULAR ULTRASOUND #CARDIOLOGY #LESIONS #REVASCULARIZATION #IMPLANTATION #THROMBOSIS #SAFETY #Cardiac & Cardiovascular Systems
Tipo

article

original article

publishedVersion